The Pfizer and BioNTech’s coronavirus vaccine is effective at blocking the disease and vaccinated people showed ‘dramatically lower’ rates of infection, a new study has found.
Researchers from the companies, who teamed up with the Israeli Ministry of Health, said this week that the COVID-19 was 97 perfect effective at preventing symptomatic cases, hospitalizations and deaths.
What’s more, the jab was 94 percent effective at preventing asymptomatic cases – which means the inoculation may be able to dramatically reduce transmission.
Those who were unvaccinated were 44 times more likely to develop symptomatic COVID-19 and 29 times more likely to die from the disease, researchers also found.
The results are in line with the 95 percent efficacy Pfizer and BioNTech reported from their late-stage clinical trial in December last year.
The latest analysis had researchers measuring results two weeks after the second dose, which suggests that although there be high efficacy after the initial dose, protection is boosted once both doses are given.
‘This clearly demonstrates the power of the Covid-19 vaccine to fight this virus,’ Yeheskel Levy, director of the health ministry, said in a statement.
‘We aim to achieve even higher uptake in people of all ages, which gives us hope of regaining normal economic and social function in the not-so-distant future.’
The study was conducted from data collected between January 17 and March 6, 2021, when the Pfizer-BioNTech vaccine was the only vaccine available in Israel.
Findings from the study have not yet been peer-reviewed but the researchers do plan to submit the data to a scientific journal.
Since vaccinations began rolling out in December 2020, Israel has led the world in mass immunizations.
Over 55 percent of the nation’s population as received at least one dose and 43 percent have received both doses, Health Ministry data show.